Cargando…

Activity of Delafloxacin When Tested Against Bacterial Surveillance Isolates Collected in the US and Europe During 2014–2016 as Part of a Global Surveillance Program

BACKGROUND: Delafloxacin (DLX) is an investigational anionic fluoroquinolone with an NDA that is under US FDA review to treat acute bacterial skin and skin structure infections and is undergoing Phase 3 studies to treat community-acquired bacterial pneumonia. METHODS: A total of 36,683 Gram-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flamm, Robert K, Shortridge, Dee, Huband, Michael D, McCurdy, Sandra, Pfaller, Michael A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630863/ http://dx.doi.org/10.1093/ofid/ofx163.918

Ejemplares similares

Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe as Part of the 2016 SENTRY Antimicrobial Surveillance Program
por: Pfaller, Michael A., et al.
Publicado: (2018)

In Vitro Evaluation of Delafloxacin Activity when Tested Against Contemporary community-Acquired Bacterial Respiratory Tract Infection Isolates (2014–2016): Results from the Sentry Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2017)

Activity of Ceftolozane-Tazobactam and Comparators When Tested against Bacterial Surveillance Isolates Collected from Pediatric Patients in the US during 2012–2016 as Part of a Global Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2017)

2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
por: Shortridge, Dee, et al.
Publicado: (2018)

1582. Delafloxacin Activity Against Drug-Resistant Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, and Moraxella catarrhalis from US Medical Centers (2014–2018)
por: Shortridge, Dee, et al.
Publicado: (2019)

In Vitro Activity of Omadacycline and Comparator Compounds Against Gram-positive Isolates Collected in the USA During 2016 as Part of a Global Surveillance Program
por: Huband, Michael D, et al.
Publicado: (2017)

155. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Community-Acquired Pneumonia and Community-Acquired Lower Respiratory Tract Infections: Results from the SENTRY Antimicrobial Surveillance Program (2014-2020)
por: Shortridge, Dee, et al.
Publicado: (2021)

2176. In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019-2021)
por: Shortridge, Dee, et al.
Publicado: (2022)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

Delafloxacin In Vitro Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone
por: Pfaller, M. A., et al.
Publicado: (2018)

1463. Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019)
por: Shorttidge, Dee, et al.
Publicado: (2020)

Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa from ICU vs. non-ICU Isolates Collected in US Medical Centers
por: Shortridge, Dee, et al.
Publicado: (2017)

Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19)
por: Sader, Helio S, et al.
Publicado: (2021)

Antimicrobial Activity of Ceftolozane–Tazobactam Tested against Contemporary (2012–2016) Enterobacteriaceae and Pseudomonas aeruginosa Isolates by US Census Division
por: Shortridge, Dee, et al.
Publicado: (2017)

2754. Delafloxacin and Comparator Fluoroquinolone In Vitro Resistance Trends in Isolates from Skin and Skin Structure Infections in the USA (2017–2022)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
por: Pfaller, Michael A., et al.
Publicado: (2017)

Geographic and Temporal Patterns of Antimicrobial Resistance in Pseudomonas aeruginosa Over 20 Years From the SENTRY Antimicrobial Surveillance Program, 1997–2016
por: Shortridge, Dee, et al.
Publicado: (2019)

Ceftolozane/Tazobactam Activity Against Drug-Resistant Pseudomonas aeruginosa and Enterobacterales Causing Healthcare-Associated Infections in Eight Asian Countries: Report from an Antimicrobial Surveillance Program (2016–2018)
por: Pfaller, Michael, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
por: Shortridge, Dee, et al.
Publicado: (2022)

37. Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016–2019)
por: Sader, Helio S, et al.
Publicado: (2020)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
por: McCurdy, Sandra P., et al.
Publicado: (2022)

Broad In Vitro Activity Analysis of Tedizolid Compared with Other Agents against a Global Collection of Gram-Positive Isolates Causing Bloodstream Infections (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program
por: Diekema, Daniel J, et al.
Publicado: (2019)

Ceftobiprole Activity When Tested Against Contemporary Bacteria Causing Bloodstream Infections in the US (2016)
por: Flamm, Robert K, et al.
Publicado: (2017)

In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections
por: McCurdy, S., et al.
Publicado: (2017)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

1047. Global Surveillance: Susceptibility of Ceftolozane–Tazobactam Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa Isolates Collected From Bloodstream Infections in the United States From 2015 to 2017
por: Arends, S J Ryan, et al.
Publicado: (2018)

Comparison of the In Vitro Susceptibility of Ceftolozane-Tazobactam With the Cumulative Susceptibility Rates of Standard Antibiotic Combinations When Tested Against Pseudomonas aeruginosa From ICU Patients With Bloodstream Infections or Pneumonia
por: Shortridge, Dee, et al.
Publicado: (2019)

1260. Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018-2019) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2020)

Temporal and Geographic Variation in Antimicrobial Susceptibility and Resistance Patterns of Enterococci: Results From the SENTRY Antimicrobial Surveillance Program, 1997–2016
por: Pfaller, Michael A, et al.
Publicado: (2019)

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020)
por: Pfaller, M. A., et al.
Publicado: (2022)

665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections
por: Huband, Michael D, et al.
Publicado: (2019)

Activity of Tedizolid against Gram-Positive Clinical Isolates Causing Nosocomial- and Community-Acquired Infections in United States Hospitals (2014–2016)
por: Mendes, Rodrigo E, et al.
Publicado: (2017)

Prevalence of mcr-type genes among colistin-resistant Enterobacteriaceae collected in 2014-2016 as part of the INFORM global surveillance program
por: Wise, Mark G., et al.
Publicado: (2018)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

2043. In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020-2021) Stratified by Infection Type
por: Huband, Michael D, et al.
Publicado: (2022)

Evaluation of In Vitro Activity of Ceftaroline Tested against Streptococcus pneumoniae Isolates from United States Hospitals: Results from 7 Years of the AWARE Surveillance Program (2010–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

Enterovirus and Parechovirus Surveillance — United States, 2014–2016
por: Abedi, Glen R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sbttithoi2mo9nf66j9br46097